Zura Bio director granted 51,000 stock options

Zura Bio Ltd director Mark Eisner received a grant of share options for 51,000 Class A Ordinary Shares.

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Zura Bio Ltd director Mark Eisner received a grant of share options for 51,000 Class A Ordinary Shares. The options have an exercise price of $3.62 per share and expire on June 17, 2036. This is a compensation-related award, not an open-market purchase or sale.

The option vests in twelve substantially equal monthly installments over a one-year period measured from June 17, 2026, subject to his continued service. Any remaining unvested portion will vest on the day immediately before the next annual meeting of shareholders following the grant date. After this award, Eisner holds 51,000 options directly.

Insider Trade Summary

Grant/Award: 51,000 shares

Grant/Award 1 txn

Insider Eisner Mark

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Share Option (Right to Buy)	51,000	$0.00	$0.00

Holdings After Transaction: Share Option (Right to Buy) — 51,000 contracts (Direct)

Footnotes (1)

F1. This option vests in twelve substantially equal monthly installments over a one-year period measured from June 17, 2026; provided, that any remaining unvested portion of the option award will vest as of the day immediately preceding the next annual meeting of shareholders following the grant date, subject to the Reporting Person's continued service as of each such vesting date.

Key Figures

Option grant size: 51,000 options Exercise price: $3.62 per share Expiration date: June 17, 2036 +2 more

5 metrics

Option grant size 51,000 options Share Option (Right to Buy) linked to Class A Ordinary Shares

Exercise price $3.62 per share Conversion or exercise price for granted options

Expiration date June 17, 2036 Option expiration date for this grant

Vesting start reference June 17, 2026 One-year monthly vesting period measured from this date

Post-grant holdings 51,000 options Total share options held directly following this transaction

Key Terms

Share Option (Right to Buy), Class A Ordinary Shares, exercise price, vests in twelve substantially equal monthly installments, +1 more

5 terms

Class A Ordinary Shares financial

"underlying_security_title: "Class A Ordinary Shares""

Class A ordinary shares are a type of ownership stake in a company that typically grants voting rights to shareholders, allowing them to have a say in important company decisions. They often come with priority in receiving dividends or profits, making them attractive to investors seeking influence and potential income. These shares help distinguish different levels of ownership and rights within a company's stock structure.

exercise price financial

"conversion_or_exercise_price: "3.6200""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vests in twelve substantially equal monthly installments financial

"This option vests in twelve substantially equal monthly installments over a one-year period"

annual meeting of shareholders financial

"immediately preceding the next annual meeting of shareholders following the grant date"

A yearly gathering where a company’s owners (shareholders) vote on key items like electing the board, approving executive pay, and ratifying auditors, and receive updates on performance and strategy. Think of it as an annual town hall for owners: it matters to investors because outcomes and disclosures can affect leadership, corporate direction, dividend and governance policies, and therefore the company’s risk and potential return.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Zura Bio (ZURA) director Mark Eisner receive in this Form 4?

Mark Eisner received a grant of 51,000 share options linked to Class A Ordinary Shares. These options are a compensation award, not a market purchase, and give him the right to buy shares at a fixed exercise price in the future.

What is the exercise price and expiration date of Eisner’s Zura Bio options?

The options carry an exercise price of $3.62 per share and expire on June 17, 2036. This means Eisner can choose to buy the underlying shares at $3.62 any time before that expiration date, once the options have vested.

How do Mark Eisner’s Zura Bio options vest over time?

The 51,000-share option vests in twelve substantially equal monthly installments over a one-year period starting on June 17, 2026. Vesting is conditioned on Eisner’s continued service with the company on each vesting date specified in the award terms.

Is there any accelerated vesting feature in Eisner’s Zura Bio option grant?

Yes. Any remaining unvested portion of the option award will vest on the day immediately before the next annual meeting of shareholders following the grant date. This accelerated vesting feature still requires Eisner’s continued service through that vesting date.

Does this Zura Bio Form 4 show Eisner buying or selling shares on the market?

No. The Form 4 reports a grant of share options as compensation, coded as an acquisition (A) rather than a market trade. There are no reported open-market purchases or sales of Zura Bio shares associated with this particular filing.

How many Zura Bio options does Mark Eisner hold after this reported grant?

Following this grant, Eisner is reported as holding 51,000 share options directly. Each option is exercisable for one Class A Ordinary Share at an exercise price of $3.62, subject to the vesting schedule and the stated expiration date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 06/22/2026 - 04:15 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Eisner Mark

(Last)

(First)

(Middle)

C/O ZURA BIO LIMITED

1489 W. WARM SPRINGS RD. #110

(Street)

HENDERSON

NEVADA

89014

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Zura Bio Ltd [ ZURA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Share Option (Right to Buy)	$3.62	06/17/2026		A		51,000		⁽¹⁾	06/17/2036	Class A Ordinary Shares	51,000	$0	51,000	D

Explanation of Responses:

1. This option vests in twelve substantially equal monthly installments over a one-year period measured from June 17, 2026; provided, that any remaining unvested portion of the option award will vest as of the day immediately preceding the next annual meeting of shareholders following the grant date, subject to the Reporting Person's continued service as of each such vesting date.

	/s/ Kim Davis, Attorney-in-Fact	06/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR